Key result
Ataluren effectively slows the loss of motor function in ambulatory patients with nonsense mutation Duchenne muscular dystrophy based on the totality of evidence from clinical trials and real-world registries.
Why the study?
The marketing authorization for ataluren in nonsense mutation Duchenne muscular dystrophy was recently withdrawn by the European Commission following a negative recommendation from the EMA.
Does ataluren slow disease progression and preserve motor function in patients with nonsense mutation Duchenne muscular dystrophy?
Does ataluren slow disease progression and preserve motor function in patients with nonsense mutation Duchenne muscular dystrophy?
The Italian Association of Myology argues against the withdrawal of ataluren, highlighting its consistent signals of efficacy in preserving motor function and delaying loss of ambulation in nmDMD.
Answers are grounded in this paper and cite their sources.
May support continued ataluren access in nmDMD; leaves open need for confirmatory RCTs.
) for the treatment of nonsense mutation Duchenne muscular dystrophy. The marketing authorization has been recently withdrawn by the European Commission following a recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency. This negative recommendation was based on the fact that three randomized controlled trials of ataluren in nonsense mutation Duchenne muscular dystrophy (007, 020, and 041) have failed to show statistically significant differencs in favor of the treatment in the selected primary outcomes for each individual study, i.e., 6-min walk distance, in the intent-to-treat population for 007 and 020 and in a subgroup for 041. However, observed differences always favored treatment, and several clinically meaningful secondary outcomes were positive and statistically significant across studies. Importantly, the largest and longest phase III study (041) showed a statistically significant effect in favor of ataluren in the wider intent-to-treat population. Furthermore, a long-term registry of "real-world" ataluren treatment data (Strategic Targeting of Registries and Database of Excellence, STRIDE), in addition to confirming a reassuring safety profile, suggested a prolonged maintenance of ambulatory, upper limb, and respiratory function. We deem that a withdrawal of ataluren from the European market would harm not only patients with nonsense mutation Duchenne muscular dystrophy, but the whole neuromuscular field, in which clinical trials are challenging because of the heterogenous complex slow-progressing nature of the disorders.
No takes yet. Share an insight, caveat, or question.
Bello et al. (2025) conducted a review in Nonsense mutation Duchenne muscular dystrophy. Ataluren vs. Placebo was evaluated. Ataluren effectively slows the loss of motor function in ambulatory patients with nonsense mutation Duchenne muscular dystrophy based on the totality of evidence from clinical trials and real-world registries.
Synapse has enriched 10 related papers. Consider them for comparative context: